Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035854 · ClinicalTrials.gov registry record · Phase 3
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT00035854 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 13 participants.
The verdict
NCT00035854, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
Interventions
- DRUG Zyvox® / Linezolid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2002-02 |
| Est. Completion | 2004-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035854
The ClinicalTrials.gov registry entry for NCT00035854 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zyvox® / Linezolid is the first listed.
NCT00035854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035854 about?
NCT00035854 is a clinical study titled "New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)". This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
What is the current status of trial NCT00035854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2002-02. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00035854?
The interventions under investigation include: Zyvox® / Linezolid (DRUG).
Who is sponsoring clinical trial NCT00035854?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.